Laropiprant

DB11629ApprovedWithdrawnSmall molecule

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Chemical structure of Laropiprant
Mechanism
Curator reviewed
Formula / weight
C21H19ClFNO4S · 435.89 g/mol (avg)
Code names
MK-0524

Resolves to

Compound
UNIIG7N11T8O78CAS571170-77-9ChEMBLCHEMBL426559ChEBI135942
Clinical / RWD
PharmGKBPA166129564
Structure
InChIKeyNXFFJDQHYLNEJK-CYBMUJFWSA-NSMILESCS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
Targets
Q13258PTGDRP43116PTGER2P43088PTGFRQ9Y5Y4PTGDR2P43119PTGIRP21731TBXA2RP04035HMGCR

What you can answer from here — as of June 15, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
35Clinical trialsPhase, status and sponsor resolved per trial
Sign in
34Marketed productsAcross 2 countries and 2 labellers
Sign in
21+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Laropiprant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In